Shares of Incyte rose more than 6 percent in Friday trade on news that the pharmaceutical company will join the S&P 500. » Read More
The death rate from drug overdoses more than doubled between 1999 and 2015, according to a report from the CDC. » Read More
By: Ylan Mui
CNBC's Ylan Mui discusses how the Trump administration's planned overhaul of the tax code could impact inversion deals and drug companies. » Read More
“We price our drugs in line with their innovation potential and in line with the competitive environment,” Werner Baumann, CEO of Bayer, told CNBC.
Arix Bioscience CEO Dr Joe Anderson discusses investment in biotechnology, adding that academic science is the focus of innovation in the industry.
Shares of Bristol-Myers climbed as much as 4 percent after billionaire Carl Icahn reportedly took a stake in the company, according to Dow Jones.
Shkreli is accused of ripping off his former pharma company Retrophin to pay off hedge-fund investors he was accused of defrauding.
Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration.
Recursion Pharmaceuticals is using robots to find treatments for rare diseases like sickle cell anemia and cystic fibrosis.
While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert.
A fire alarm rang out moments before indicted former pharmaceutical executive Martin Shkreli was to speak at Harvard University.
Dermatologists and other specialists are three times more likely than primary care providers to prescribe brand name versions of drugs known as topical immunomodulators.
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.
By 2030, 70 percent of HIV patients will be over 50. Now success of HIV drugs poses a new challenge: treating it as a geriatric condition.
Nadav Kidron, CEO of Oramed Pharmaceuticals, talks about the company's latest offering and the issue of drug pricing.
The drug was found to be generally well-tolerated with no serious adverse events or discontinuations reported, the company said.
Marathon says it will charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.
Allergan said it would buy Zeltiq Aesthetics for about $2.48 billion to gain access to its flagship body contouring technology.
Marathon said the muscular dystrophy drug will cost $89,000 a year, but that the company will provide a "robust" assistance program for uninsured patients.
Get the best of CNBC in your inbox